{"id":973413,"date":"2026-06-17T22:13:36","date_gmt":"2026-06-18T02:13:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/"},"modified":"2026-06-17T22:13:36","modified_gmt":"2026-06-18T02:13:36","slug":"kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/","title":{"rendered":"Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm"},"content":{"rendered":"
\n

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT)<\/u><\/strong> breached their fiduciary duties to shareholders.<\/p>\n

According to a federal securities lawsuit, Corcept Therapeutics Incorporated failed to disclose adverse facts concerning potential FDA approval of one of the Company\u2019s lead new product candidates, relacorilant, a medication being developed for multiple indications, including the treatment of hypercortisolism, or Cushing\u2019s syndrome. While the Company touted the expected success of FDA approval, it failed to disclose that the FDA had in fact expressed concerns to Corcept about the adequacy of the Company’s clinical development program assessing relacorilant\u2019s effectiveness and that relacorilant’s New Drug Application faced a material risk of rejection.<\/p>\n

If you currently own CORT and purchased prior to October 31, 2024 <\/strong>please contact\u00a0Justin Kuehn, Esq. by email at\u00a0justin@kuehn.law<\/a> or call (833) 672-0814.\u00a0 Kuehn Law pays all case costs and does not charge its investor clients.<\/strong>Shareholders should contact the firm immediately as there may be limited time to enforce your rights.<\/em><\/p>\n

\n Why Your Participation Matters:<\/strong>\n <\/p>\n

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.<\/em>\u2122\u00a0\u00a0<\/p>\n

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law<\/a>.<\/p>\n

Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law<\/a>
(833) 672-0814<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Corcept Therapeutics Incorporated failed to disclose adverse facts concerning potential FDA approval of one of the Company\u2019s lead new product candidates, relacorilant, a medication being developed for multiple indications, including the treatment of hypercortisolism, or Cushing\u2019s syndrome. While the Company touted the expected success of FDA approval, it failed to disclose that the FDA had in fact expressed concerns to Corcept about the adequacy of the Company’s clinical development program assessing relacorilant\u2019s effectiveness and that relacorilant’s New Drug Application … <\/p>\n

Continue reading “Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-973413","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Corcept Therapeutics Incorporated failed to disclose adverse facts concerning potential FDA approval of one of the Company\u2019s lead new product candidates, relacorilant, a medication being developed for multiple indications, including the treatment of hypercortisolism, or Cushing\u2019s syndrome. While the Company touted the expected success of FDA approval, it failed to disclose that the FDA had in fact expressed concerns to Corcept about the adequacy of the Company’s clinical development program assessing relacorilant\u2019s effectiveness and that relacorilant’s New Drug Application … Continue reading "Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-18T02:13:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0OTAxNCM3NjY3NjgwIzIyODUyNTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm\",\"datePublished\":\"2026-06-18T02:13:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\\\/\"},\"wordCount\":258,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0OTAxNCM3NjY3NjgwIzIyODUyNTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\\\/\",\"name\":\"Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0OTAxNCM3NjY3NjgwIzIyODUyNTU=\",\"datePublished\":\"2026-06-18T02:13:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0OTAxNCM3NjY3NjgwIzIyODUyNTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0OTAxNCM3NjY3NjgwIzIyODUyNTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/","og_locale":"en_US","og_type":"article","og_title":"Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm - Market Newsdesk","og_description":"NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Corcept Therapeutics Incorporated failed to disclose adverse facts concerning potential FDA approval of one of the Company\u2019s lead new product candidates, relacorilant, a medication being developed for multiple indications, including the treatment of hypercortisolism, or Cushing\u2019s syndrome. While the Company touted the expected success of FDA approval, it failed to disclose that the FDA had in fact expressed concerns to Corcept about the adequacy of the Company’s clinical development program assessing relacorilant\u2019s effectiveness and that relacorilant’s New Drug Application … Continue reading \"Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-18T02:13:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0OTAxNCM3NjY3NjgwIzIyODUyNTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm","datePublished":"2026-06-18T02:13:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/"},"wordCount":258,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0OTAxNCM3NjY3NjgwIzIyODUyNTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/","name":"Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0OTAxNCM3NjY3NjgwIzIyODUyNTU=","datePublished":"2026-06-18T02:13:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0OTAxNCM3NjY3NjgwIzIyODUyNTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0OTAxNCM3NjY3NjgwIzIyODUyNTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kuehn-law-encourages-investors-of-corcept-therapeutics-incorporated-to-contact-law-firm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/973413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=973413"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/973413\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=973413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=973413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=973413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}